No Data
No Data
Insider Spends US$183k Buying More Shares In Immuneering
Investors who take an interest in Immuneering Corporation (NASDAQ:IMRX) should definitely note that the Director, Peter Feinberg, recently paid US$2.44 per share to buy US$183k worth of the stock.
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination -- Phase 1 portion of
Immuneering Announces First Patient Dosed in Its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering Corporation (Nasdaq: IMRX) today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations.
Immuneering(IMRX.US) Director Buys US$7,384.85 in Common Stocks
$Immuneering(IMRX.US)$ Director Schall Thomas J. purchased 2,900 shares of Common Stocks on Mar 22, 2024 at an average price of $2.5465 for a total value of $7,384.85.Source: Announcement What is stat
Immuneering(IMRX.US) Director Buys US$63,712.5 in Common Stocks
$Immuneering(IMRX.US)$ Director Feinberg Peter purchased 25,000 shares of Common Stocks on Mar 22, 2024 at an average price of $2.5485 for a total value of $63,712.5.Source: Announcement What is state
Immuneering(IMRX.US) Officer Buys US$10,015.2 in Common Stocks
$Immuneering(IMRX.US)$ Officer Brakewood Harold Eugene purchased 3,900 shares of Common Stocks on Mar 22, 2024 at an average price of $2.568 for a total value of $10,015.2.Source: Announcement What is
No Data